Tumor Targeting via EPR: Strategies to Enhance Patient Responses

By Susanne K Golombek, Jan-Niklas May, Benjamin Theek, Lia Appold, N. Drude, Fabian Kiessling, T. Lammers. Advanced Drug Delivery Reviews, 2018

1,055 citations recorded by the source corpus.

The tumor accumulation of nanomedicines relies on the enhanced permeability and retention (EPR) effect. In the last 5-10 years, it has been increasingly recognized that there is a large inter- and intra-individual heterogeneity in EPR-mediated tumor targeting, explaining the heterogeneous outcomes of clinical trials in which nanomedicine formulations have been evaluated. To address this heterogeneity, as in other areas of oncology drug development, we have to move away from a one-size-fits-all tumor targeting approach, towards methods that can be employed to individualize and improve nanomedicine treatments. To this end, efforts have to be invested in better understanding the nature, the complexity and the heterogeneity of the EPR effect, and in establishing systems and strategies to enhance, combine, bypass and image EPR-based tumor targeting. In the present manuscript, we summarize key studies in which these strategies are explored, and we discuss how these approaches can be employed to enhance patient responses.

Subfields: Biomaterials, Biomedical Engineering, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/1a84c67309bcac6cfa63e35a01aef0b74b7cf2d5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Yajun Wang
T. Gong
Yongliang Cao
Yongkai Cao
Dahua Fan
Meiqun Cao

Citations in the corpus

Nanomedicine in cancer therapy (2023, background): “28,48 Although some auxiliary approaches could be exploited to partially address the heterogeneity of the EPR effect and improve EPR-based tumor targeting, there are still many patients suffering from tumors with non-leaky blood vessels that cannot bene ﬁ t from the EPR-mediated tumor-selective…”